Pay in 4 interest-free payments of $7.06 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
With a focused emphasis on semaglutide as the leading case study, the paper provides integrated, actionable insights to support pharmaceutical companies, regulators, and healthcare systems in managing market transition, safeguarding quality and access, and sustaining innovation in the evolving GLP-1 landscape
Semaglutide, marketed as Ozempic and Wegovy, has been called a breakthrough in weight management
Recognizing these patterns early can help you build a routine that feels more sustainable and easier to follow long-term
Abordaje de factores contribuyentes: Evaluar y tratar condiciones coexistentes que dificultan la prdida de peso: resistencia a la insulina, sndrome de ovario poliqustico, apnea del sueo, deficiencia de vitamina D (comn en Hashimoto) y trastornos del estado de nimo
Morgan & Claypool Life Sciences
US$ 23.57
US$ 29.89
US$ 21.71
US$ 27.06
US$ 29.04
